Skip to main content
. 2020 Dec 9;25(2):729–741. doi: 10.1111/jcmm.16122

FIGURE 7.

FIGURE 7

Proposed mechanism underlying the reduced left ventricular stiffening in metabolic syndrome‐induced cardiac disease after linagliptin administration. F passive, passive stiffness; N2Bus, N2B unique sequence; PEVK, proline (P), glutamic acid (E), valine (V) and lysine (K)